Overview
- Description
The company develops next-generation surgical implants using electrospun nanofiber scaffolds and smart biomaterials to repair and regenerate soft tissues, with its FDA-cleared flagship product, ArtiFascia®, targeting dural repair and a broader $17bn+ market in internal surgeries.
- Website
- Country
- Israel
- Sector
- Medical Technologies
*By clicking here you will be leaving the official EIC website and you will be directed to the Dealroom.co domain, an official EISMEA contractor for the EIC investor matchmaking platform.